Biotech Startups

FinalDose develops a programmable DNA-targeting molecule designed to recognize and destroy cells carrying specific genetic sequences, with initial applications in oncology across cancer types.

7 investors

Formo is a biotechnology company using fermentation and microbiology to create animal-free dairy products through molecular recreation rather than plant-based mimicry. The company serves the food and dairy industry with sustainable alternatives to conventional dairy.

7 investors

Functional Fluidics is a CLIA-certified diagnostic lab offering proprietary red blood cell function biomarker assays, starting with Sickle Cell Disease. It provides contract research services and biomarker testing to clinical providers, pharmaceutical, biotech, and academic partners to support drug development and patient care, with operations in the US and Sub-Saharan Africa.

7 investors

Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead asset, DMR-001, is an investigational monoclonal antibody targeting mutCALR, with a first regulatory submission planned for mid-2026.

7 investors

General Sense develops detection technology that augments trained detection animals, aiming to identify molecular threats such as narcotics, crop diseases, human diseases, and bioweapons. It offers higher sensitivity and objective digital readouts to make detection a passive, more reliable task than relying on traditional detection dogs alone.

7 investors

Generare is building a library of naturally evolved molecules by reading and analyzing biological chemistry that has not been previously studied.

7 investors

New cardiac scanning method for diagnostics.

7 investors

Genomenon uses AI to read biomedical literature and expert scientists to curate variant- and patient-level genomic evidence, delivering regulatory-grade real-world evidence. Its products, including Mastermind and CKB, serve drug development teams and clinical genetic testing labs for variant interpretation and drug program decisions.

7 investors

Gesynta Pharma is a pharmaceutical company developing non-hormonal, anti-inflammatory drug candidates that inhibit the mPGES-1 enzyme, with a lead program in endometriosis. Its pipeline targets inflammation- and pain-related conditions across clinical development stages.

7 investors

GlycanAge offers glycan-based biological age testing and insights to help individuals understand their health and aging rate through advanced diagnostics. The company serves consumers and medical professionals interested in personalized longevity and preventive healthcare.

7 investors

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

7 investors

Groundwork BioAg makes Rootella, a mycorrhizal soil inoculant that farmers apply to their fields, and runs the Rootella Carbon Program that lets growers earn carbon-credit income while improving soil health. It targets agricultural growers, distributing up to 70% of net carbon-credit proceeds to a farmer pool.

7 investors

Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases. The company serves patients, families, and advocates in the rare disease community through novel drug development and patient-centered approaches.

7 investors

Healionics develops STARgraft, a synthetic vascular graft built on its STAR biomaterial scaffold that resists occlusion and infection to create a reliable bloodstream access site for kidney dialysis patients. The device has received FDA Breakthrough Device designation and targets the treatment of kidney failure through dialysis.

7 investors

Heartseed develops cardiac regenerative medicine, creating heart muscle cells from iPS cells for transplantation to treat heart failure, with its lead pipeline HS-001 nearing clinical trials. The company targets patients with heart failure caused by conditions such as myocardial infarction, with reference markets in Japan and the US.

7 investors

Helaina uses precision fermentation to produce human proteins, including lactoferrin and other bioactive nutrients found in human milk, for consumer nutrition products serving athletes, new parents, and health-conscious consumers.

7 investors

Hydregen develops biocatalysis platform technologies that integrate into existing chemical manufacturing infrastructure, aiming to cut process costs by 40-50% while lowering energy use and carbon emissions. It sells to chemical manufacturers, supporting UK and EU needs for secure critical chemical supply chains.

7 investors

ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company developing immune therapies for immune-excluded tumors, which resist standard PD-1 blockade. Its lead candidate, IMGS-001, is a cytotoxic immune checkpoint inhibitor aimed at cancers such as colorectal, ovarian, and non–small cell lung cancer.

7 investors

Inductive Bio builds AI and machine learning software to accelerate drug discovery for pharmaceutical and biotech researchers, combining computational chemistry with expertise in translating complex drug programs from preclinical to clinical stages.

7 investors

Industrial Microbes (iMicrobes) designs and engineers microbes to produce chemicals more cheaply and with lower environmental impact. It works with large companies to use alternative raw materials and recycle waste for applications in chemical production, polymers, agriculture, and space exploration.

7 investors

Infinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants. The company operates in the infant health and microbiome therapeutics space.

7 investors

InGel Therapeutics develops engineered cell therapies for complex retinal degenerative diseases, combining retinal precursor cells with a biomimetic hyaluronic acid and gelatin hydrogel delivery matrix that mimics the human vitreous. The company also runs Regenesis, a target discovery platform using single-cell proteomics to identify neuroprotective pathways in the eye.

7 investors

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines. The company serves patients and pharmaceutical development by integrating in vitro lab data with human clinical data to decode biology and unlock transformative treatments.

7 investors

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

7 investors